Key terms
About BPTH
Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1002, and BP1003. The company was founded by Peter H. Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest BPTH news
Mar 12
2:14pm ET
Bio-Path Holdings trading resumes
Mar 12
2:09pm ET
Bio-Path Holdings trading halted, volatility trading pause
Mar 08
5:16pm ET
Bio-Path files to sell 1.15M shares of common stock, warrants
Mar 08
7:02am ET
Bio-Path reports FY23 EPS ($33.63) vs ($38.12) last year
Feb 23
7:12am ET
Bio-Path Holdings Announces Consolidating Reverse Stock Split
Feb 22
7:50pm ET
Bio-Path Holdings trading halted, news pending
Feb 21
7:11am ET
Bio-Path announces 1-for-20 reverse stock split
Jan 10
7:10am ET
Bio-Path completes first dose escalation part of Phase 1 trial of BP1002
Dec 22
4:09pm ET
Bio-Path files to sell common stock, warrants, no amount given
Dec 14
7:01am ET
Bio-Path completes first doses cohort of Phase 1/1b trial of BP1002
No recent news articles are available for BPTH
Aug 30
1:11pm ET
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q2 23
Jun 02
12:49pm ET
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 23
Apr 10
1:25pm ET
Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q4 '22
BPTH Financials
Key terms
Ad Feedback
BPTH Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
BPTH Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range